Catalyst Event
Teva Pharmaceutical Industries Ltd (TEVA) · Other
From KEDI Global Longevity Bio Index (KGLB)
6/4/2026, 12:00:00 AM
Teva announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea, in several European markets including France, Germany, Spain, and The Netherlands, which began in May 2026.
Korean Translation
2026년 5월부터 프랑스, 독일, 스페인, 네덜란드를 포함한 여러 유럽 시장에서 아일리아(Eylea)의 바이오시밀러인 아잔티브(AHZANTIVE) 출시를 발표함.
Related Recent Events
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for a decision on the approval of the seasonal flu vaccine candidate (mRNA-1010) is scheduled for 2026-08-05, which is estimated to cause a ≥5% price impact scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
GSK plc (GSK) · Earnings Release
GSK's second quarter 2026 earnings release scheduled. Routine earnings releases typically result in a price impact of approximately 1-3%.
7/28/2026, 12:00:00 AM
Revvity Inc (RVTY) · Earnings Release
Revvity's Q2 2026 earnings release is scheduled for 2026-07-27.
7/27/2026, 12:00:00 AM